This site contains promotional content intended for UK Healthcare Professionals and other relevant decision makers | Not a HCP? Visit our  Public Site.
Adverse Event reporting can be found at the bottom of the page | Prescribing Information for the relevant medicine can be found adjacent to the below content and/or in the footer below. 

Cardiovascular
Cardiovascular
Womens Health
Women's Health
two kidneys
Nephrology
Oncology
Oncology
Ophthalmology
Ophthalmology
Respiratory
Respiratory
Bayer for ProfessionalsYour Resource Portal
Resources

mCRPC Patient Case Study: An Oncologist perspective

Bayer has collaborated with healthcare professionals across the multidisciplinary team to develop a series of patient case studies.

Xofigo Header Image

These case studies were developed as a promotional educational resource and share real-world experience from experts on the treatment and management of their patients with metastatic castration-resistant prostate cancer (mCRPC). Each case study covers the whole patient journey, from initial diagnosis and treatment decisions to outcomes and tolerability.

These case studies share a range of different patient profiles including different ages, treatment histories, concomitant medications and outcomes to help visualise and identify eligible mCRPC patients who may be suitable for treatment with Xofigo.

mCRPC Patient Case Study: An Oncologist perspective

By Dr Aspasia Soultati, Consultant Medical Oncologist, Brighton and Sussex University Hospital, NHS Foundation Trust, Brighton.

Patient: 89 years old when diagnosed with advanced prostate cancer who was chemo-ineligible due to his age, comorbidities, and performance status.

Treatment goal: Improve symptomatic control of bone pain and slow down the decline of quality of life during on-treatment period vs placebo. 4th line treatment with Xofigo.

Xofigo▼ Prescribing Information

This patient case study is initiated and funded by Bayer plc. No patient identifiable data or photos of patients are shared within these case studies and the appropriate consent from the patients was collected by the HCP prior to development. Individual responses and experiences to medicinal products may vary.

Speakers
    • Dr Aspasia Soultati
      Dr Aspasia Soultati

    Dr Aspasia Soultati is a Medical Oncologist with a specialist interest in Genitourinary and Colorectal cancers. She completed her specialty training in Athens, Greece and Guys & St Thomas, London. Aspasia has a strong research interest having obtained a PhD in Athens, and her post-doctoral translational research was in Renal cancers with a team of world renowned scientists, led by Professor C Swanton, at the Francis Crick Institute, London.

    Currently, she treats patients with Colorectal and GI cancers at Eastbourne District General Hospital (EDGH) and is the Oncology Lead for the unit at Eastbourne and Conquest. Aspasia is currently responsible for the delivery of chemotherapy and the holistic care of colorectal and urology oncology patients across Eastbourne and Hastings. She supervises a team of mixed workforce professionals including pharmacists, CNS and physician associates who are currently reviewing patients in clinic under her guidance and support.

    As part of her Leadership role she has designed, proposed, and co led the strategic development, reconfiguration, and expansion on the EDGH oncology service, with the deployment of new methods of service provision (consultant Led service mixed workforce model). Her aspiration is to help transform the experience of oncology patients receiving treatment across Sussex through promoting high quality clinical practice and encouraging clinical research.

mCRPC Patient Case Study
A Nuclear Medicine perspective - Xofigo®▼ (radium-223 dichloride)
PP-XOF-GB-0575, June 2024

PP-XOF-GB-0574 | June 2024

    • 1
      Xofigo® Summary of Product Characteristics.